Preclinical Research

  • Preclinical Research
  • Regulatory Comparisons for Starting First-In-Human Clinical Trials

    Preclinical Resource Library

     

    A Wealth of Information at Your Fingertips

    Altasciences has an extensive understanding and decades of experience in IND/NDA-enabling toxicology, safety pharmacology, and laboratory services that meet global regulatory requirements.

    Here are some of our most insightful scientific resources in preclinical development to guide you through every step of the journey:

    VISIT THE FULL LIBRARY

    Speak with an expert today to learn more about our preclinical solution.

    Have five more minutes? Check out these web pages:

    Preclinical Services
    Miniature Swine in Nonclinical Studies

    In Case You Missed It: Webinar on Safety Assessment of Gene Therapy Products

     

    If you missed our latest webinar titled Nonclinical Safety Assessment of Gene Therapy Products, it’s not too late! The on-demand version is now available.

    Topics covered include:

    •    current trends in the development of gene therapy products;
    •    timing of biodistribution studies based on the ICH S12 Guideline;
    •    planning considerations and requirements for toxicity studies; and
    •    AAVs NAbs pre-dose screening data for animal selection.

    Watch it now!
     

    If you have questions about your nonclinical cell and gene therapy studies, speak with one of our experts.


    You may also be interested in:
    eBook: Key Considerations for Cell and Gene Therapy Nonclinical Studies
    Scientific Poster: Gene Therapy Utilizing Adeno-Associated Viral (AAV) Vectors
    Scientific Journal: Applications of PCR Analysis for Your Gene Therapy Programs

    Insights on Dermal Toxicology Studies for FDA Filings

     

     

    Essentials for Successful Dermal Safety Testing


    Altasciences’ team of preclinical research experts, including toxicologists, veterinarians, and technicians, have extensive experience and a solid understanding of the challenges specific to dermal research. In this eBook, we answer critical questions and highlight key considerations to help you advance your dermal program from discovery through clinical trials to proof-of-concept, and beyond.

    You’ll learn about:

    •    important factors to consider before starting your dermal research program;
    •    questions you can expect our preclinical research team to ask you;
    •    the data required for regulatory agencies; and
    •    available FDA pathways and how to choose the right one for your molecule.

    Ready to begin? Altasciences’ preclinical research team can design and conduct studies that reliably and quickly provide you with the data you need, from initial efficacy work through IND-enabling programs and regulatory submissions. We can develop new dermal models, validate existing ones, and perform GLP and non-GLP toxicology studies to support both 505(b)(2) and new chemical entity regulatory filings. Get started today!

    Most Recent Scientific Posters Presented by Our Preclinical Experts

     

    DELVE INTO A SPECTRUM OF PRECLINICAL TOPICS BELOW

    Get ready for a must-read experience! We are pleased to share with you seven new scientific posters we presented at the 44th Annual American College of Toxicology (ACT) Meeting.

    Delve into a spectrum of preclinical topics below: 

    •    Introducing the Philippine Cynomolgus Macaque (Macaca Fascicularis Philippensis) as a Research Model in Drug Safety Assessment. Yafei Chen, MS, Senior Research Fellow

    •    Comparison of Cardiovascular and Respiratory Parameters in Three Strains of Research Pigs; Sinclair Nanopig™, Göttingen Minipig®, and Yucatan™ Miniature Swine. Miri Pannu, MS, Associate Scientific Director

    •    Creation of a Swine Model of Oral Angioedema. Kyle Klepner, Senior Study Director

    •    Intravenous Sampling and Administration in Rodents: Overcoming Challenges of Using Vascular Access Buttons™. 
    Dr. Gabriela Campoy, DVM, Associate Scientist, Study Director

    •    Understanding Species Variation in the Occurrence of Spontaneous Background Eye Lesions in Toxicology Studies: A Comparative Study. Dr. Nirmala Chinnappareddy, BVSc, PhD, DABT, ERT, Scientist/Study Director

    •    Historical Review of In-Life Data from Preclinical Studies Utilizing AAVs for Gene Therapy. Julie Forget, DESS Tox, DABT, Senior Director Safety Assessment

    •    Proposed Best Practices for Optimizing the Number of Animals in Toxicology Studies. Narine Lalayeva, MS, Associate Director, Safety Assessment

    Questions? Speak with one of our experts about your small or large molecule preclinical projects. We can get your study started within the next two months!
     
    SUBMIT AN INQUIRY  
     

    Subscribe to Preclinical Research